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BRIEF COMMUNICATION
Estimating the Population Benefits of 
Blood Pressure Lowering: A Wide- Angled 
Mendelian Randomization Study in UK 
Biobank
Hannah Higgins , MPhil; Amy M. Mason , PhD; Susanna C. Larsson , PhD;  
Dipender Gill , BMBCh, PhD; Claudia Langenberg , MD, PhD; Stephen Burgess , PhD
BACKGROUND: The causal relevance of elevated blood pressure for several cardiovascular diseases (CVDs) is uncertain, as is 
the population impact of blood pressure lowering. This study systematically assesses evidence of causality for various CVDs 
in a 2- sample Mendelian randomization framework, and estimates the potential reduction in the prevalence of these diseases 
attributable to long- term population shifts in the distribution of systolic blood pressure (SBP).
METHODS AND RESULTS: We investigated associations of genetically predicted SBP as predicted by 256 genetic variants with 21 
CVDs in UK Biobank, a population- based cohort of UK residents. The sample consisted of 376 703 participants of European 
ancestry, aged 40 to 69 years at recruitment. Genetically predicted SBP was positively associated with 14 of the outcomes 
(P<0.002), including dilated cardiomyopathy, endocarditis, peripheral vascular disease, and rheumatic heart disease. Using 
genetic variation to estimate the long- term impact of blood pressure lowering on disease in a middle- aged to early late- aged 
UK- based population, population reductions in SBP were predicted to result in an overall 16.9% (95% CI, 12.2%– 21.3%) 
decrease in morbidity for a 5– mm Hg decrease from a population mean of 137.7 mm Hg, 30.8% (95% CI, 22.8%– 38.0%) 
decrease for a 10– mm Hg decrease, and 56.2% (95% CI, 43.7%– 65.9%) decrease for a 22.7– mm Hg decrease in SBP 
(22.7 mm Hg represents a shift from the current mean SBP to 115 mm Hg).
CONCLUSIONS: Risk of many CVDs is influenced by long- term differences in SBP. The burden of a broad range of CVDs could 
be substantially reduced by long- term population- wide reductions in the distribution of blood pressure.
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High blood pressure has severe, costly conse-quences largely through increased cardiovascu-lar disease (CVD) risk.1 For many CVDs, a causal 
relationship with blood pressure that is reversible 
through treatment has been demonstrated in random-
ized controlled trials (RCTs).2 However, for diseases 
such as dilated cardiomyopathy, endocarditis, periph-
eral vascular disease, and aortic valve stenosis, RCT 
evidence demonstrating a causal effect of blood pres-
sure lowering is lacking. Despite this, these outcomes 
have been used to estimate the population impact of 
increased blood pressure.3 In addition, quantitative ev-
idence for the benefit of reducing blood pressure has 
not been assessed for several CVD outcomes in a pri-
mary prevention setting.
In the absence of RCT evidence, Mendelian ran-
domization (MR) can circumvent several limitations of 
observational epidemiology, allowing unconfounded 
inferences from observational data.4 MR uses selected 
genetic variants related to an exposure to provide 
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evidence supporting a causal hypothesis. The inde-
pendent segregation of alleles at conception means 
that genetically defined subgroups of the population 
with increased or decreased average blood pressure 
levels should not differ systematically with respect to 
confounding variables, creating a natural experiment 
analogous to an RCT. Life- long average differences in 
the exposure between subgroups compared in an MR 
analysis provide evidence on the potential impact of 
long- term interventions on the exposure, in contrast to 
the short- term interventions usually evaluated by RCTs.5
Herein, we use MR to assess evidence for causal-
ity between systolic blood pressure (SBP) and a broad 
range of CVDs in UK Biobank, a population- based co-
hort of UK residents. We then use these estimates to 
predict the potential reduction in CVD burden in the UK 
population attributable to distributional shifts in SBP. We 
focus on SBP as a measure of blood pressure because 
it is a better predictor of health outcomes than diastolic 
blood pressure.1 However, as the genetic variants used 
in this investigation are associated with both SBP and 
diastolic blood pressure, estimates relate generally to 
blood pressure lowering and are not specific to SBP.
METHODS
Summarized genetic data used in this investigation have 
been made publicly available and can be accessed at 
https://doi.org/10.6084/m9.figsh are.14417 594.v1. The 
UK Biobank study was approved by the UK’s North 
West Multi- Centre Research Ethics Committee. All par-
ticipants provided written informed consent.
We performed 2- sample MR analyses using sum-
marized data (Figure  S1). Genetic associations with 
blood pressure were obtained in an analysis of 299 024 
European ancestry participants from the International 
Consortium for Blood Pressure, which excluded UK 
Biobank participants.6 Genetic associations with 21 
CVDs were estimated in 376 703 European ancestry 
participants from UK Biobank by logistic regression 
with adjustment for age, sex, and 10 genomic princi-
pal components (Table S1). Derivation of the analytic 
subset followed quality control steps described pre-
viously7: after filtering genetic variants (call rate ≥99%, 
information score >0.9, and Hardy- Weinberg equi-
librium P≥10−5) and participants (removal of genetic 
sex mismatches), we excluded participants having 
non- European ancestries (self- report or inferred by 
genetics) or excess heterozygosity (>3 SDs from the 
mean), and included only one of each set of related 
participants (third- degree relatives or closer).
As genetic instruments, we selected 256 vari-
ants previously associated with blood pressure at a 
genome- wide level of significance in the International 
Consortium for Blood Pressure data set, excluding UK 
Biobank participants (Table  S2). As the International 
Consortium for Blood Pressure and UK Biobank sam-
ples do not overlap, bias attributable to winner’s curse 
is avoided. The variants explained 2.1% of variance in 
SBP in International Consortium for Blood Pressure, 
corresponding to an F- statistic of 23.1. Associations 
between a weighted genetic risk score and potential 
confounders (sex, age, body mass index [BMI], smok-
ing status, low- density lipoprotein [LDL] cholesterol, 
alcohol drinker status, glycated hemoglobin, history of 
diabetes mellitus at recruitment, and physical activity) 
were assessed in UK Biobank.
Statistical analysis
MR estimates for the casual effect of SBP on the 
odds of 21 CVD outcomes were obtained using the 
inverse variance weighted (IVW) method.4 Estimates 
are odds ratios per 10– mm Hg increase in genetically 
predicted SBP. Sensitivity analyses were performed 
using the MR- Egger, weighted median, and Mendelian 
Randomization- Pleiotropy Residual Sum and Outlier 
(MR- PRESSO) methods.4
The plausibility of estimates derived from MR having 
a causal interpretation relies on genetic variants satis-
fying 3 assumptions: the genetic variant is associated 
with the exposure of interest (the relevance assump-
tion); the genetic variant can only influence the out-
come through its effect on the exposure (the exclusion 
restriction assumption); and the genetic variant is not 
associated with the outcome via a confounding path-
way (the exchangeability assumption). The IVW method 
assumes that all genetic variants satisfy these assump-
tions, or that the average pleiotropic effect across ge-
netic variants is zero.4 The additional methods provide 
reliable inferences when some genetic variants violate 
these assumptions, allowing investigation of the robust-
ness of results. The MR- Egger method relaxes the IVW 
assumption that the average pleiotropic effect is zero, 
allowing for directional pleiotropy when the pleiotropic 
effects of the genetic variants on the outcome are not 
correlated with their associations with the exposure. 
The weighted median method takes a median (instead 
of a weighted mean) of the variant- specific estimates, 
providing an estimate robust to outlying variants. In the 
MR- PRESSO method, variants with heterogeneous es-
timates (which may be pleiotropic variants) are excluded 
from the analysis, and the IVW method is subsequently 
performed, omitting such variants.
Outcomes with consistent evidence for causality 
(P<0.05/21=0.002 in either the IVW or the MR- PRESSO 
method and concordant direction of estimates across 
all methods) were used to estimate the change in dis-
ease burden that would occur under interventions in 
the distribution of SBP. Assuming a linear model, we 
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the relative reduction in disease risk if mean SBP was 
set to a given value for all individuals in the population. 
We also estimated the absolute reduction in events 
from a population shift in the distribution of SBP using 
disease prevalence estimates from surveys relevant to 
a middle- aged to early late- aged UK- based population 
(Table S3).
All analyses were performed in R version 3.6.3 
(“Holding the Windsock”).
RESULTS
SBP was approximately normally distributed, with a mean 
of 137.7 mm Hg (SD, 18.6 mm Hg) (Figure S2). There was 
no association between the genetic risk score and age, 
sex, smoking, physical activity, glycated hemoglobin, or 
alcohol consumption (Table). The genetic risk score was 
associated with SBP, BMI, LDL cholesterol, and history 
of diabetes mellitus, but the absolute magnitude of as-
sociations other than with SBP was small (mean differ-
ence between top versus bottom 50%: 4.1 mm Hg for 
SBP, −0.1 kg/m2 for BMI, −0.04 mmol/L for LDL cho-
lesterol, and 0.4% for prevalence of diabetes mellitus 
history). Indeed, any pleiotropic influence of BMI or LDL 
cholesterol would generally result in underestimation of 
the effect of SBP as both BMI and LDL cholesterol in-
crease the risk of most CVDs.
Fourteen outcomes satisfied the criteria of con-
sistent evidence for causality: P<0.002 in either the 
IVW or the MR- PRESSO method and concordance 
of estimates across methods (Figure 1 and Table S4). 
In decreasing order of the IVW estimate, these were: 
aortic valve stenosis, ischemic stroke, dilated cardio-
myopathy, coronary artery disease, subarachnoid 
hemorrhage, ischemic cerebrovascular disease, en-
docarditis, hemorrhagic stroke (all), chronic kidney 
disease, heart failure, transient ischemic attack, atrial 
fibrillation, rheumatic heart disease, and peripheral 
vascular disease (Figure  S3). Two further outcomes 
(intracerebral hemorrhage and aortic aneurysm) had a 
positive IVW estimate at a conventional level of statisti-
cal significance (P<0.05). Deep vein thrombosis had an 
inverse IVW estimate at a conventional level of statisti-
cal significance (P<0.05).
Figure 2 shows the estimated changes in the ab-
solute prevalence of outcomes with consistent evi-
dence for causality resulting from a population shift 
in the distribution of SBP. Population impact frac-
tions for these outcomes are provided in Table  S5. 
Aggregating across these outcomes, reductions 
Figure 1. Mendelian randomization estimates (odds ratio with 95% CI per 10– mm Hg increase in genetically predicted 
systolic blood pressure) from the inverse variance weighted method.
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in SBP were predicted to result in an overall 16.9% 
(95% CI, 12.2%– 21.3%) decrease in CVD morbidity for 
a 5– mm Hg SBP decrease from a population mean 
of 137.7 mm Hg, 30.8% (95% CI, 22.8%– 38.0%) de-
crease for a 10– mm  Hg SBP decrease, and 56.2% 
(95% CI, 43.7%– 65.9%) decrease for a 22.7– mm Hg 
SBP decrease. The value of 22.7 mm Hg represents 
a shift from the current mean SBP in the population 
to 115 mm Hg, a value that has been proposed as a 
theoretical minimum risk target.3
DISCUSSION
Although for many CVDs, the causal effect of blood 
pressure lowering has been demonstrated convinc-
ingly in RCTs, several outcomes (dilated cardiomyo-
pathy, endocarditis, peripheral vascular disease, and 
rheumatic heart disease) had previously only been 
shown to be associated with SBP in observational 
studies.1,3 Our analysis adds evidential weight to blood 
pressure as a causal risk factor for these outcomes 
Figure 2. Bar chart showing the prevalence and estimated changes if lifelong systolic blood 
pressure (SBP) decreased across its distribution by 5, 10, or 22.7 mm Hg (22.7 mm Hg represents a 
shift from the current mean of 137.7 to 115 mm Hg) separately for each cardiovascular outcome and 
for high- prevalence outcomes (current UK prevalence >200 per 10 000) (A) and lower- prevalence 
outcomes (current UK prevalence <200 per 10 000) (B).
Ischemic cerebrovascular disease (all) comprises ischemic stroke and transient ischemic attack. 









Chronic Kidney Disease Coronary Artery Disease Ischemic Cerebrovascular
Disease (All)












Legend: Mean Popula on SBP (distribu onal shi ):













Aor c Valve Stenosis Hemorrhagic Stroke
(All)




















 http://ahajournals.org by on Septem
ber 24, 2021
J Am Heart Assoc. 2021;10:e021098. DOI: 10.1161/JAHA.121.021098 5
Higgins et al Population Benefits of Lower Blood Pressure
and to their inclusion in other SBP population impact 
studies.
Although most of the outcomes associated with 
genetically predicted SBP are chronic diseases, some 
have infectious origins (eg, endocarditis and rheu-
matic heart disease). Elevated SBP may therefore in-
crease susceptibility to, or damage from, infection. A 
notable finding was the inverse association between 
genetically predicted SBP and deep vein thrombosis. 
Although this association did not achieve statistical 
significance after accounting for multiple testing, some 
evidence for an inverse association between SBP and 
venous thromboembolism has been found in previous 
observational studies.8
The MR estimates obtained herein were generally 
larger than those from RCTs and conventional obser-
vational analyses. For example, the MR estimate for 
the risk of ischemic stroke per 10– mm Hg increase in 
SBP was an odds ratio of 1.70 (95% CI, 1.52– 1.90). 
This contrasts with relative risk estimates of 1.37 (95% 
CI, 1.30– 1.47) from a recent meta- analysis of RCTs,2 
and 1.53 (95% CI, 1.49– 1.56) for stroke in 60- to 
69- year- old people in the observational analysis of the 
Prospective Studies Collaboration.9 Although some 
difference between estimates is expected as MR es-
timates represent the lifelong impact of elevated blood 
pressure, whereas RCTs vary blood pressure for a 
shorter period, other factors, such as trial setting and 
inclusion criteria, may also contribute to differences.
This study has many strengths, but also limitations. 
The large sample size and wide range of outcomes en-
able systematic cross- comparisons of unconfounded 
estimates in a single cohort. This is important from a 
public health perspective when comparing the impact 
of the same genetic change on different diseases. The 
genome- wide genotypic data available from the UK 
Biobank cohort absolved any need to use proxy vari-
ants in the instrument. However, the results should be 
interpreted in the context of several limitations.
First, the UK Biobank cohort is somewhat unrep-
resentative of the UK population and experiences a 
“healthy volunteer” selection bias.10 Analyses were 
conducted in participants of European descent to 
avoid population stratification. Estimates may there-
fore not be fully relevant for the whole UK population. 
Whether the findings are applicable to other races/
ethnicities warrants investigation, particularly because 
hypertension disproportionately affects Black African 
and Caribbean ancestry racial/ethnic groups in both 
the UK and abroad.11 Given large global disparities in 
hypertension prevalence, generalizability of the public 
health modeling beyond the United Kingdom may be 
limited.
The MR approach is underpinned by assump-
tions that cannot be completely empirically validated. 
However, the genetic risk score for SBP was not 
strongly associated with major confounders, and es-
timates were generally similar across robust methods.
Table 1. Characteristics of Participants in the Analytic Subset of the UK Biobank Study
Characteristics Overall
Genetic risk score percentile
P valueLower 50% Upper 50%
No. of participants 367 703 183 822 183 821 …
Age at survey, mean (SD), y 57.2 (8.0) 57.2 (8.0) 57.2 (8.0) 0.26
Women, n (%) 198 902 (54.1) 99 564 (54.2) 99 307 (54.0) 0.39
Body mass index, mean (SD), kg/m2 27.4 (4.8) 27.4 (4.8) 27.3 (4.7) <0.001
Low- density lipoprotein, mean (SD), mmol/L 3.57 (0.87) 3.59 (0.87) 3.55 (0.87) <0.001
HbA1c, mean (SD), mmol/mol 35.9 (6.4) 35.9 (6.4) 35.9 (6.5) 0.10
History of diabetes mellitus at recruitment, n (%) 16 927 (4.6) 8082 (4.4) 8843 (4.8) <0.001
Physical activity, mean (SD), MET min/wk 2660 (2710) 2650 (2710) 2669 (2709) 0.06
Deaths, n (%) 8033 (2.2) 3925 (2.1) 4105 (2.2) 0.04
Cardiovascular events, n (%) 7145 (1.9) 3291 (1.8) 3853 (2.1) <0.001
Cardiovascular events (fatal), n (%) 1422 (0.4) 682 (0.4) 740 (0.4) 0.12
Cardiovascular events (nonfatal), n (%) 5723 (1.6) 2609 (1.4) 3113 (1.7) <0.001
Cerebrovascular events (fatal), n (%) 2714 (0.7) 1217 (0.7) 1497 (0.8) <0.001
Current smokers, n (%) 37 866 (10.3) 19 099 (10.4) 18 763 (10.2) 0.07
Current alcohol drinkers, n (%) 342 797 (93.4) 171 486 (93.4) 171 260 (93.3) 0.25
Participants taking antihypertensives, n (%) 74 556 (20.4) 29 841 (16.4) 44 702 (24.5) <0.001
Systolic blood pressure, mean (SD), mm Hg 137.7 (18.6) 135.6 (18.2) 139.7 (18.8) <0.001
Diastolic blood pressure, mean (SD), mm Hg 82.0 (10.1) 81.1 (10.0) 82.8 (10.2) <0.001
Genetic risk score was calculated from 256 variants previously associated with a blood pressure trait at P<5×10−8 in data from the International Consortium 
for Blood Pressure, excluding UK Biobank participants. Physical activity is measured in MET minutes per week, and is taken from Data Field 22 040. HbA1c 
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Although the principles of MR seek to emulate an 
RCT, the approach differs fundamentally in certain 
aspects, which are relevant when using MR in pub-
lic health modeling. First, the results presented herein 
reflect lifelong differences in SBP relating to genetic 
variants that are determined at conception. The re-
versibility of these long- term effects is unknown; how-
ever, reversibility is assumed in the population impact 
fraction calculations. Although SBP- associated risks 
have demonstrated reversibility in RCTs for most car-
diovascular outcomes, it is unknown whether this ap-
plies to the full spectrum of outcomes studied herein. 
There may be no existing intervention applicable to a 
mature cohort that can imitate the genetic effect, and 
if such an intervention does exist, the time lag or age 
at treatment onset required to produce the predicted 
effects is unknown. For context, antihypertensive drug 
treatment reduced SBP by 8.3 mm Hg in patients aged 
30 to 49 years, 10.7 mm Hg in patients aged 60 to 79 
years, and 9.4 mm Hg in patients aged >80 years in a 
meta- analysis of RCTs of patients with isolated systolic 
hypertension (SBP >160  mm  Hg).12 Population- wide 
shifts in the distribution of SBP using nonclinical in-
terventions are generally much smaller in magnitude 
and occur over much larger time frames: for example, 
the UK population’s average SBP has decreased by 
≈3 mm Hg between 2003 and 2017.11
There are several limitations to use of the popula-
tion impact factors. First, our results are tailored to a 
middle- aged to early late- aged UK- based population. 
We focus on this group as the estimates obtained from 
UK Biobank are most relevant to this population. We 
did not attempt subgroup or interaction analyses to in-
vestigate the impact of blood pressure lowering in dif-
ferent subgroups of the population, or in groups with 
comorbidities. The population impact fraction measure 
used herein assumes independence of effects on dif-
ferent outcomes; in reality, the outcomes considered 
are frequently consequential or coincident in patients. 
However, although dependence between the out-
comes would inflate CIs for the public health modeling 
estimates, it would not affect the estimates themselves 
as the expected value of the sum of estimates is equal 
to the sum of the expectations of the estimates, even 
if the estimates are correlated. Finally, these analyses 
assume linearity of effects. Estimates are likely to be 
reliable for shifts in SBP of similar magnitude to the 
genetic associations with SBP, which are around 8 to 
10 mm Hg.4 The appropriateness of extrapolation to 
larger changes in SBP cannot be assessed in this cur-
rent study.
The evidence presented herein suggests that inci-
dence of CVDs is influenced by long- term differences 
in the distribution of SBP, even in a population- based 
sample. Therefore, confining blood pressure– lowering 
interventions to older age groups and individuals over 
a certain risk threshold will likely only partially address 
the totality of disease burden. Although these estimates 
constitute a modeling exercise and not an intervention 
analysis, they do provide evidence to support a life 
course approach to lowering population SBP. Several 
other publications support this stance. A recent MR 
study found evidence indicating a linear relationship of 
genetically predicted SBP with coronary artery disease, 
further supporting the conclusion that even individuals 
with SBP in the normal range can benefit from public 
health interventions achieving persistent SBP reduc-
tion for the primary prevention of CVD.13 In another MR 
investigation, naturally occurring random allocation to 
higher SBP instrumented by multiple common genetic 
variants was associated with a significantly faster in-
crease in SBP with age, and this increased exposure 
to elevated blood pressure had a cumulative detrimen-
tal effect on the risk of coronary heart disease greater 
than that observed in RCTs.14 Further work has used 
the observation that some genetic predictors of blood 
pressure more strongly predict midlife blood pressure, 
whereas others more strongly predict later- life blood 
pressure. Genetically predicted midlife blood pressure 
was shown to be independently associated with cor-
onary artery disease risk when conditioning on later- 
life blood pressure, suggesting that these represent 
distinct risk factors.15 Interventions that target the de-
terminants of high blood pressure at early stages in 
the life course, and earlier identification and treatment 
of those with high blood pressure, are therefore more 
likely to yield the large effect sizes observed herein 
than those that only target people already in a later 
stage of life. This provides an important opportunity to 
reduce the inequality in health outcomes along the so-
cioeconomic gradient. Interventions that may replicate 
the lifelong reduction in exposure to elevated SBP eval-
uated herein include nonpharmacologic interventions, 
such as increased physical activity, weight control, and 
sodium reductions, as well as community- wide pro-
grams, such as consumer awareness campaigns and 
industry collaboration for food reformulation.
In conclusion, reducing SBP by 10 mm Hg could 
reduce the overall burden of a broad range of CVDs 
by around 30%. These findings contribute to an ever- 
expanding body of evidence advocating targeted and 
population- based strategies for management of high 
blood pressure across the life course.
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Table S1. Summary of disease outcomes considered, definitions, and sources of information 












































Ischemic Stroke 433.X, 434.X I63.X, I64.X Non-cancer illness code (20002) 
Transient Ischemic 












Hemorrhage 430.X I60.X 
Non-cancer illness 
code (20002) 


























































Disease 443.8, 443.9 I73.8, I73.9 
Non-cancer illness 
code (20002) 
Aortic Valve Stenosis 424.1 I35.0, I35.2 Non-cancer illness code (20002) 

















Endocarditis 391.1, 421.0, 421.9, 421.1 












Disease 585.X N18.X 
Non-cancer illness 
code (20002) 
Note that .X means that all sub-codes are matched. 
Abbreviations: ICD, International Classification of Disease; OPCS, Office of Population Censuses and Surveys Classification 
of Surgical Operations and Procedures. 
*Health condition diagnosed by doctor (6150/6152) and Medication for health condition (6177) were self-reported from 
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Table S2. Details of the 256 single nucleotide polymorphisms (SNPs) from the International 
Consortium for Blood Pressure (ICBP) genome-wide association study (GWAS) included in the 
genetic instrument. 𝛽𝛽𝑥𝑥𝑥𝑥 corresponds to the variant-SBP association estimates (beta-coefficients in 
mmHg units). These variants are taken from Supplementary Table 24 of Evangelou et al, Nat Genet 


















rs10057188 5 77837789 A G 0.4516 5.0E-05 5.5E-02 -1.9E-01 4.8E-02 4.4E-05 
rs10059921 5 87514515 T G 0.0846 5.8E-05 6.3E-02 -3.7E-01 9.2E-02 4.9E-05 
rs10077885 5 114390121 A C 0.498 8.2E-05 8.9E-02 -2.5E-01 4.8E-02 3.5E-07 
rs10078021 5 75038431 G T 0.3744 4.8E-06 5.3E-03 6.2E-02 4.9E-02 2.1E-01 
rs10224002 7 151415041 G A 0.2814 6.1E-05 6.7E-02 2.4E-01 5.3E-02 6.0E-06 
rs1036477 15 48914926 G A 0.1044 5.8E-05 6.3E-02 -3.4E-01 7.4E-02 4.1E-06 
rs10418305 19 15278808 G C 0.897 3.0E-06 3.3E-03 7.8E-02 7.5E-02 3.0E-01 
rs1055144 7 25871109 T C 0.1925 9.7E-06 1.1E-02 1.1E-01 5.8E-02 6.3E-02 
rs1060105 12 123806219 T C 0.2021 8.8E-06 9.6E-03 -1.0E-01 5.7E-02 7.9E-02 
rs1063281 2 218668732 T C 0.6045 7.3E-05 8.0E-02 -2.4E-01 4.8E-02 7.1E-07 
rs10818775 9 125755571 T C 0.1236 4.3E-05 4.7E-02 -2.7E-01 7.0E-02 8.7E-05 
rs10826995 10 32082658 C T 0.2787 8.7E-06 9.5E-03 9.0E-02 5.1E-02 8.1E-02 
rs10850411 12 115387796 C T 0.3006 1.0E-04 1.1E-01 -3.0E-01 4.9E-02 8.1E-10 
rs10922502 1 89360158 G A 0.3593 6.4E-05 7.0E-02 2.3E-01 4.8E-02 2.3E-06 
rs10943605 6 79655477 A G 0.4886 4.1E-05 4.5E-02 1.7E-01 4.6E-02 1.6E-04 
rs11008355 10 31412561 C G 0.2369 7.1E-06 7.7E-03 -8.6E-02 5.4E-02 1.1E-01 
rs11030119 11 27728102 A G 0.2944 3.2E-05 3.5E-02 -1.7E-01 5.1E-02 8.5E-04 
rs110419 11 8252853 G A 0.5071 8.8E-06 9.6E-03 -8.1E-02 4.7E-02 8.5E-02 
rs11067763 12 116198341 G A 0.1031 1.8E-05 2.0E-02 -1.9E-01 7.5E-02 1.1E-02 
rs111245230 9 113169775 C T 0.0338 8.4E-05 9.2E-02 6.9E-01 1.3E-01 1.0E-07 
rs11128722 3 14958126 A G 0.5628 8.4E-05 9.1E-02 -2.5E-01 4.7E-02 8.5E-08 
rs11154027 6 121781390 C T 0.5513 1.1E-07 1.2E-04 9.0E-03 4.8E-02 8.5E-01 
rs11191548 10 104846178 C T 0.0871 4.5E-04 4.9E-01 -1.0E+00 8.2E-02 6.2E-36 
rs112184198 10 102604514 A G 0.1058 1.4E-04 1.6E-01 -5.3E-01 7.6E-02 2.4E-12 
rs11229457 11 58207203 T C 0.2144 7.5E-05 8.2E-02 -2.9E-01 5.6E-02 3.0E-07 
rs112557609 1 56576924 A G 0.3414 6.9E-05 7.5E-02 2.4E-01 4.9E-02 1.1E-06 
rs1126464 16 89704365 C G 0.245 3.4E-05 3.7E-02 1.8E-01 5.7E-02 1.1E-03 
rs1126930 12 49399132 C G 0.0343 5.9E-05 6.4E-02 5.8E-01 1.4E-01 3.9E-05 
rs11537751 11 47587452 T C 0.0521 4.1E-05 4.5E-02 3.9E-01 1.1E-01 2.6E-04 
rs11556924 7 129663496 T C 0.3713 7.8E-05 8.5E-02 -2.5E-01 5.0E-02 5.9E-07 
rs11639856 16 24788645 A T 0.1902 4.3E-05 4.7E-02 -2.3E-01 5.8E-02 6.8E-05 
rs11689667 2 85491365 C T 0.4536 1.9E-05 2.1E-02 -1.2E-01 4.7E-02 1.1E-02 
rs11690961 2 46363336 C A 0.116 2.9E-07 3.1E-04 -2.3E-02 7.2E-02 7.5E-01 
rs11701033 21 33788341 G C 0.1831 4.9E-05 5.3E-02 2.5E-01 5.9E-02 3.2E-05 
rs1173771 5 32815028 G A 0.6024 3.5E-04 3.8E-01 5.2E-01 4.7E-02 6.0E-29 
rs11953630 5 157845402 T C 0.3694 2.5E-04 2.7E-01 -4.5E-01 5.0E-02 5.2E-19 
rs11977526 7 46008110 A G 0.3993 8.3E-05 9.0E-02 -2.5E-01 4.8E-02 1.6E-07 
rs12374077 3 185317674 C G 0.3452 3.5E-05 3.8E-02 1.7E-01 4.8E-02 4.6E-04 
rs12405515 1 172357441 T G 0.5741 3.9E-05 4.2E-02 -1.7E-01 4.6E-02 2.0E-04 
rs12408022 1 217718789 T C 0.2611 6.5E-05 7.1E-02 2.5E-01 5.3E-02 2.4E-06 
rs12521868 5 131784393 T G 0.4156 2.0E-05 2.2E-02 -1.2E-01 4.8E-02 9.7E-03 
rs12579720 12 20173764 G C 0.7621 8.9E-05 9.7E-02 3.0E-01 5.4E-02 2.5E-08 
rs12627651 21 44760603 A G 0.2944 1.9E-04 2.1E-01 4.2E-01 5.3E-02 3.3E-15 
rs12628032 22 19967980 T C 0.3152 4.5E-05 4.9E-02 2.0E-01 5.0E-02 7.7E-05 
rs1275988 2 26914364 T C 0.6055 3.4E-04 3.7E-01 -5.2E-01 4.7E-02 1.8E-28 
rs12906962 15 95312071 C T 0.3293 8.4E-05 9.2E-02 2.7E-01 4.9E-02 6.4E-08 
rs12921187 16 4943019 G T 0.5726 7.7E-05 8.4E-02 2.4E-01 4.6E-02 1.3E-07 
rs12940887 17 47402807 T C 0.3727 8.9E-05 9.7E-02 2.7E-01 4.7E-02 1.4E-08 
rs12941318 17 1333598 C T 0.5018 5.8E-05 6.3E-02 2.1E-01 4.8E-02 1.7E-05 
rs12946454 17 43208121 T A 0.261 1.1E-04 1.2E-01 3.2E-01 5.2E-02 7.3E-10 
rs12958173 18 42141977 C A 0.7 1.4E-04 1.5E-01 -3.5E-01 5.0E-02 1.2E-12 
rs13082711 3 27537909 C T 0.231 7.5E-05 8.2E-02 2.8E-01 5.5E-02 2.8E-07 
rs13107325 4 103188709 T C 0.0722 2.8E-04 3.0E-01 -8.8E-01 9.5E-02 1.8E-20 























rs13139571 4 156645513 A C 0.2393 8.6E-05 9.3E-02 -3.0E-01 5.4E-02 3.7E-08 
rs13205180 6 51832494 T C 0.4808 2.3E-06 2.5E-03 4.1E-02 4.6E-02 3.8E-01 
rs13209747 6 127115454 T C 0.4465 2.2E-04 2.5E-01 4.1E-01 4.7E-02 9.8E-19 
rs1322639 6 169587103 A G 0.7711 7.5E-06 8.2E-03 8.9E-02 5.6E-02 1.1E-01 
rs13238550 7 131059056 A G 0.3909 3.7E-05 4.0E-02 1.7E-01 4.7E-02 3.3E-04 
rs1327235 20 10969030 G A 0.4631 1.7E-04 1.8E-01 3.5E-01 4.5E-02 3.2E-15 
rs13303 3 52558008 C T 0.5697 1.6E-05 1.7E-02 1.1E-01 4.7E-02 2.1E-02 
rs13333226 16 20365654 G A 0.186 9.2E-05 1.0E-01 -3.4E-01 5.8E-02 7.0E-09 
rs13359291 5 122476457 A G 0.1654 1.2E-04 1.3E-01 4.0E-01 6.2E-02 1.1E-10 
rs13420463 2 37517566 G A 0.2225 7.0E-05 7.7E-02 -2.8E-01 5.6E-02 7.2E-07 
rs1344653 2 19730845 G A 0.5039 3.3E-05 3.6E-02 1.6E-01 4.6E-02 5.8E-04 
rs1378942 15 75077367 A C 0.6563 2.9E-04 3.1E-01 -4.9E-01 4.8E-02 5.0E-24 
rs143112823 3 154707967 A G 0.076 6.1E-05 6.6E-02 -4.0E-01 9.5E-02 2.3E-05 
rs1438896 2 145646072 C T 0.7001 5.8E-05 6.4E-02 -2.3E-01 5.0E-02 5.4E-06 
rs1446468 2 164963486 C T 0.5488 3.2E-04 3.4E-01 4.9E-01 4.7E-02 2.3E-25 
rs1449544 8 76591880 C A 0.4584 6.5E-05 7.1E-02 -2.2E-01 4.6E-02 1.4E-06 
rs1458038 4 81164723 T C 0.2971 4.9E-04 5.4E-01 6.6E-01 5.1E-02 6.1E-39 
rs1475130 14 100225144 C T 0.6571 3.2E-05 3.5E-02 1.6E-01 4.9E-02 7.4E-04 
rs147696085 1 51021867 A G 0.1011 2.7E-06 2.9E-03 -7.4E-02 8.0E-02 3.5E-01 
rs1530440 10 63524591 T C 0.1874 2.0E-04 2.2E-01 -5.0E-01 5.9E-02 2.0E-17 
rs1563788 6 43308363 T C 0.2937 1.0E-04 1.1E-01 3.1E-01 5.0E-02 9.8E-10 
rs167479 19 11526765 T G 0.4732 2.5E-04 2.7E-01 -4.3E-01 5.6E-02 2.5E-14 
rs16823124 2 183224127 A G 0.303 6.1E-05 6.7E-02 2.3E-01 5.0E-02 3.1E-06 
rs16851397 3 141134818 G A 0.0467 8.3E-05 9.1E-02 5.9E-01 1.1E-01 1.9E-07 
rs17030613 1 113190807 C A 0.2191 1.4E-04 1.5E-01 3.9E-01 5.6E-02 2.5E-12 
rs17080102 6 151004770 C G 0.0677 1.7E-04 1.9E-01 -7.2E-01 9.2E-02 4.9E-15 
rs17249754 12 90060586 A G 0.1637 4.7E-04 5.2E-01 -8.0E-01 6.2E-02 2.2E-38 
rs17367504 1 11862778 G A 0.1556 4.3E-04 4.7E-01 -7.8E-01 6.4E-02 4.8E-34 
rs17477177 7 106411858 C T 0.2094 2.8E-04 3.1E-01 5.6E-01 5.6E-02 1.6E-23 
rs17608766 17 45013271 C T 0.1433 2.5E-04 2.7E-01 6.2E-01 6.7E-02 3.9E-20 
rs17638167 19 11584818 T C 0.047 6.6E-05 7.2E-02 -5.2E-01 1.1E-01 1.8E-06 
rs1799945 6 26091179 G C 0.1479 2.0E-04 2.2E-01 5.4E-01 6.6E-02 1.3E-16 
rs1813353 10 18707448 C T 0.3411 2.3E-04 2.5E-01 -4.3E-01 4.8E-02 3.0E-19 
rs1876487 2 73114352 C A 0.7122 7.5E-06 8.2E-03 8.3E-02 5.5E-02 1.3E-01 
rs1925153 6 56102780 T C 0.4401 3.5E-06 3.8E-03 -5.1E-02 4.9E-02 3.0E-01 
rs1953126 9 123640500 C T 0.6453 4.2E-05 4.5E-02 -1.8E-01 4.8E-02 1.2E-04 
rs1975487 2 55809054 G A 0.5124 6.5E-05 7.1E-02 2.2E-01 4.7E-02 2.9E-06 
rs2004776 1 230848702 T C 0.2381 1.1E-04 1.2E-01 3.4E-01 5.4E-02 5.3E-10 
rs2014912 4 86715670 C T 0.8485 1.8E-04 2.0E-01 -5.1E-01 6.4E-02 1.8E-15 
rs2034618 15 83799632 T C 0.2231 2.1E-07 2.3E-04 -1.5E-02 5.5E-02 7.8E-01 
rs2071518 8 120435812 T C 0.2571 4.9E-05 5.3E-02 2.2E-01 5.2E-02 3.1E-05 
rs2076328 1 1687482 T G 0.4748 1.1E-04 1.2E-01 -2.8E-01 5.0E-02 1.4E-08 
rs2107595 7 19049388 A G 0.166 6.8E-05 7.4E-02 3.0E-01 6.2E-02 1.2E-06 
rs2157597 1 169201567 T C 0.3468 8.9E-06 9.7E-03 -8.6E-02 4.9E-02 8.1E-02 
rs2240736 17 59485393 T C 0.7328 1.9E-04 2.1E-01 4.3E-01 5.3E-02 4.5E-16 
rs2246438 10 45273079 A G 0.2779 5.1E-07 5.5E-04 -2.2E-02 5.1E-02 6.7E-01 
rs2282978 7 92264410 C T 0.342 6.0E-06 6.5E-03 -7.0E-02 4.9E-02 1.5E-01 
rs2289125 11 89224453 C A 0.7697 3.6E-05 3.9E-02 1.9E-01 5.8E-02 8.5E-04 
rs2291435 4 38387395 T C 0.5248 7.8E-05 8.6E-02 -2.4E-01 4.6E-02 1.7E-07 
rs2304130 19 19789528 G A 0.0833 3.9E-05 4.2E-02 3.1E-01 8.6E-02 3.6E-04 
rs2306374 3 138119952 C T 0.1619 3.7E-05 4.1E-02 2.3E-01 6.3E-02 3.0E-04 
rs2404715 1 57008778 T C 0.0925 1.8E-05 2.0E-02 -2.0E-01 8.0E-02 1.2E-02 
rs2467099 17 73949045 T C 0.2204 3.4E-05 3.7E-02 -1.9E-01 5.5E-02 4.8E-04 
rs2493292 1 3328659 T C 0.1501 4.9E-05 5.4E-02 2.7E-01 6.8E-02 7.8E-05 
rs2521501 15 91437388 T A 0.3301 3.7E-04 4.0E-01 5.6E-01 5.2E-02 4.8E-27 
rs2579519 2 96675166 C T 0.3949 3.7E-08 4.1E-05 5.4E-03 4.8E-02 9.1E-01 
rs2645466 17 57853214 C A 0.3018 4.4E-05 4.8E-02 2.0E-01 4.9E-02 7.1E-05 
rs2759308 15 81016227 A G 0.4758 9.0E-05 9.8E-02 2.6E-01 4.6E-02 1.8E-08 
rs2761436 1 207919748 T C 0.5276 5.0E-05 5.4E-02 1.9E-01 4.6E-02 2.9E-05 























rs28427409 17 6473882 T C 0.4133 3.5E-05 3.8E-02 1.6E-01 4.6E-02 4.0E-04 
rs2898290 8 11433909 C T 0.5165 1.6E-04 1.7E-01 -3.4E-01 4.7E-02 2.1E-13 
rs2932538 1 113216543 G A 0.7414 1.2E-04 1.3E-01 3.4E-01 5.3E-02 7.2E-11 
rs2969070 7 2512545 A G 0.6369 9.4E-05 1.0E-01 -2.8E-01 4.8E-02 8.4E-09 
rs2972146 2 227100698 T G 0.6362 7.7E-05 8.4E-02 2.5E-01 4.8E-02 1.8E-07 
rs2978098 8 101676675 C A 0.442 2.9E-05 3.2E-02 -1.5E-01 4.7E-02 1.7E-03 
rs2978456 8 42324765 C T 0.4442 1.5E-05 1.7E-02 1.1E-01 5.0E-02 3.2E-02 
rs3184504 12 111884608 C T 0.5244 4.5E-04 4.9E-01 -5.8E-01 4.7E-02 2.6E-35 
rs33063 16 69640217 G A 0.856 2.1E-05 2.3E-02 -1.8E-01 6.5E-02 6.0E-03 
rs34591516 8 142367087 T C 0.0533 8.5E-05 9.3E-02 5.6E-01 1.1E-01 1.5E-07 
rs347591 3 11290122 T G 0.6625 9.7E-05 1.1E-01 2.8E-01 4.9E-02 6.3E-09 
rs34872471 10 114754071 C T 0.2936 3.6E-05 3.9E-02 1.8E-01 5.1E-02 4.2E-04 
rs35261357 16 75444572 T C 0.5698 1.0E-04 1.1E-01 2.8E-01 4.7E-02 2.7E-09 
rs35410524 6 96885405 T C 0.1917 7.5E-05 8.2E-02 3.0E-01 5.9E-02 3.4E-07 
rs35444 12 115552437 G A 0.3921 1.4E-04 1.5E-01 -3.3E-01 4.7E-02 1.8E-12 
rs35783704 8 105966258 A G 0.1092 1.4E-04 1.6E-01 -5.2E-01 7.7E-02 1.5E-11 
rs36010659 18 48283949 C T 0.1391 2.4E-05 2.7E-02 -2.0E-01 6.6E-02 3.0E-03 
rs36022378 3 49913705 C T 0.1926 2.0E-05 2.2E-02 1.6E-01 6.0E-02 9.3E-03 
rs3741378 11 65408937 T C 0.1328 1.1E-04 1.2E-01 -4.2E-01 7.0E-02 2.2E-09 
rs3771371 2 71627539 T C 0.5658 4.3E-05 4.7E-02 -1.8E-01 4.6E-02 9.2E-05 
rs381815 11 16902268 T C 0.2705 1.4E-04 1.5E-01 3.6E-01 5.2E-02 1.5E-12 
rs3820068 1 15798197 G A 0.2023 9.8E-05 1.1E-01 -3.4E-01 6.0E-02 1.7E-08 
rs3918226 7 150690176 T C 0.0811 1.2E-04 1.3E-01 5.5E-01 9.1E-02 1.8E-09 
rs409558 6 31708147 C T 0.1712 1.5E-04 1.7E-01 -4.5E-01 6.4E-02 2.6E-12 
rs419076 3 169100886 C T 0.5265 2.1E-04 2.3E-01 -3.9E-01 4.6E-02 5.4E-18 
rs4245739 1 204518842 A C 0.7326 3.0E-05 3.3E-02 1.7E-01 5.3E-02 1.2E-03 
rs4247374 19 7252756 T C 0.1355 1.6E-04 1.8E-01 -5.1E-01 7.5E-02 1.8E-11 
rs4292285 4 145271954 A T 0.3994 2.1E-05 2.3E-02 -1.3E-01 4.7E-02 5.8E-03 
rs4308 17 61559625 G A 0.6178 9.4E-05 1.0E-01 -2.7E-01 4.8E-02 1.1E-08 
rs4364717 9 21801530 G A 0.4534 1.5E-05 1.6E-02 1.1E-01 4.6E-02 1.9E-02 
rs4373814 10 18419972 C G 0.441 8.4E-05 9.2E-02 2.5E-01 4.7E-02 6.2E-08 
rs4387287 10 105677897 C A 0.8262 2.9E-05 3.2E-02 -2.0E-01 6.2E-02 1.8E-03 
rs4454254 8 141060027 A G 0.6346 6.1E-05 6.7E-02 -2.2E-01 4.8E-02 3.2E-06 
rs4494250 10 96563757 A G 0.3611 8.1E-05 8.9E-02 2.6E-01 4.9E-02 1.3E-07 
rs449789 6 159699125 G C 0.8652 1.8E-05 1.9E-02 -1.7E-01 6.8E-02 1.3E-02 
rs452036 14 23865885 A G 0.3492 2.5E-05 2.8E-02 -1.4E-01 4.8E-02 2.7E-03 
rs470113 22 40729614 G A 0.188 5.0E-06 5.5E-03 7.8E-02 5.8E-02 1.8E-01 
rs4728142 7 128573967 A G 0.4383 6.1E-05 6.7E-02 -2.2E-01 4.7E-02 3.9E-06 
rs4757391 11 16302939 T C 0.8013 2.1E-04 2.3E-01 -4.9E-01 5.7E-02 8.3E-18 
rs4823006 22 29451671 G A 0.4384 2.6E-05 2.9E-02 -1.4E-01 4.6E-02 2.0E-03 
rs4952611 2 40567743 T C 0.5834 5.9E-05 6.5E-02 -2.1E-01 4.9E-02 1.2E-05 
rs5219 11 17409572 C T 0.6245 1.3E-04 1.4E-01 -3.2E-01 4.7E-02 1.1E-11 
rs55701159 2 25139596 G T 0.113 4.8E-05 5.3E-02 -3.0E-01 7.4E-02 5.3E-05 
rs55780018 2 208526140 C T 0.452 1.4E-04 1.6E-01 3.3E-01 4.9E-02 1.9E-11 
rs57927100 17 75317300 G C 0.259 1.2E-04 1.4E-01 -3.5E-01 5.4E-02 8.4E-11 
rs6015450 20 57751117 G A 0.1287 2.6E-04 2.8E-01 6.6E-01 6.9E-02 2.4E-21 
rs60199046 1 59663341 G A 0.2868 3.5E-05 3.8E-02 -1.8E-01 5.1E-02 4.3E-04 
rs6031435 20 42797358 G A 0.4612 6.9E-05 7.5E-02 2.3E-01 4.6E-02 6.7E-07 
rs6060114 20 30169673 C T 0.162 5.8E-05 6.3E-02 -2.8E-01 6.2E-02 5.9E-06 
rs6081613 20 19465907 A G 0.2722 2.0E-05 2.1E-02 1.4E-01 5.1E-02 7.3E-03 
rs6095241 20 47308798 A G 0.4363 4.7E-05 5.1E-02 -1.9E-01 4.5E-02 3.3E-05 
rs6108168 20 8626271 A C 0.2541 4.2E-05 4.6E-02 -2.0E-01 5.2E-02 8.8E-05 
rs62011052 15 79156983 C T 0.1497 1.9E-07 2.0E-04 1.7E-02 6.4E-02 8.0E-01 
rs62104477 19 30294991 T G 0.3313 9.0E-06 9.8E-03 8.7E-02 4.9E-02 7.4E-02 
rs62270945 3 128201889 T C 0.0302 3.9E-06 4.3E-03 1.6E-01 1.6E-01 3.2E-01 
rs62524579 8 144060955 A G 0.5307 4.4E-05 4.8E-02 -1.8E-01 5.3E-02 6.9E-04 
rs6271 9 136522274 T C 0.0725 6.8E-05 7.4E-02 -4.3E-01 1.0E-01 2.1E-05 
rs633185 11 100593538 C G 0.7096 2.7E-04 3.0E-01 5.0E-01 5.1E-02 9.8E-23 
rs6429422 1 243472801 G T 0.3289 2.4E-05 2.7E-02 1.4E-01 4.9E-02 3.6E-03 























rs6557876 8 25900675 T C 0.2511 1.4E-04 1.5E-01 -3.7E-01 5.3E-02 6.0E-12 
rs6595838 5 127868199 A G 0.2891 6.2E-05 6.7E-02 2.4E-01 5.1E-02 3.1E-06 
rs661348 11 1905292 C T 0.4368 1.5E-04 1.7E-01 3.4E-01 5.0E-02 9.6E-12 
rs6686889 1 25030470 T C 0.2581 7.5E-06 8.2E-03 8.5E-02 5.3E-02 1.1E-01 
rs66887589 4 120509279 C T 0.4814 4.4E-05 4.8E-02 1.8E-01 4.6E-02 9.0E-05 
rs67330701 11 69079707 T C 0.0958 3.6E-05 3.9E-02 -2.8E-01 9.1E-02 2.4E-03 
rs6783086 3 133959552 T C 0.409 8.6E-05 9.4E-02 2.6E-01 4.7E-02 3.9E-08 
rs6797587 3 48197614 G A 0.6797 9.2E-05 1.0E-01 2.8E-01 5.0E-02 1.5E-08 
rs6825911 4 111381638 T C 0.787 5.1E-05 5.5E-02 -2.4E-01 5.8E-02 3.7E-05 
rs687621 9 136137065 G A 0.3392 1.2E-05 1.3E-02 -9.8E-02 4.8E-02 4.3E-02 
rs6891344 5 123136656 G A 0.1856 6.5E-05 7.1E-02 -2.8E-01 6.0E-02 2.2E-06 
rs6911827 6 22130601 T C 0.4623 3.1E-05 3.4E-02 1.5E-01 4.7E-02 1.3E-03 
rs6969780 7 27159136 C G 0.0961 6.4E-05 7.0E-02 3.7E-01 7.9E-02 3.1E-06 
rs709209 1 6278414 G A 0.3421 1.1E-05 1.2E-02 -9.4E-02 5.3E-02 7.6E-02 
rs7103648 11 47461783 G A 0.3844 1.2E-04 1.3E-01 3.1E-01 4.7E-02 6.2E-11 
rs7126805 11 828916 A G 0.7292 1.5E-05 1.7E-02 1.2E-01 5.6E-02 3.1E-02 
rs7129220 11 10350538 A G 0.1233 8.9E-05 9.7E-02 3.9E-01 7.2E-02 6.3E-08 
rs7178615 15 66869072 G A 0.6085 2.6E-05 2.8E-02 1.4E-01 4.7E-02 2.8E-03 
rs7236548 18 43097750 A C 0.1857 5.7E-05 6.2E-02 2.6E-01 5.8E-02 5.5E-06 
rs7248104 19 7224431 A G 0.4085 3.3E-05 3.6E-02 -1.6E-01 4.6E-02 6.0E-04 
rs7255 2 20878820 C T 0.5345 6.7E-06 7.3E-03 7.1E-02 4.7E-02 1.3E-01 
rs72765298 9 127900996 C T 0.1179 6.8E-05 7.4E-02 3.5E-01 7.3E-02 1.7E-06 
rs72799341 16 30936743 A G 0.2392 8.8E-06 9.6E-03 9.5E-02 5.4E-02 7.9E-02 
rs72812846 5 173377636 A T 0.278 6.1E-05 6.7E-02 -2.4E-01 5.3E-02 8.2E-06 
rs7297416 12 54443090 C A 0.3133 9.2E-05 1.0E-01 -2.8E-01 5.0E-02 1.8E-08 
rs7302981 12 50537815 G A 0.6131 1.8E-04 2.0E-01 -3.7E-01 4.6E-02 4.4E-16 
rs73030266 6 166179459 T A 0.0674 3.3E-05 3.6E-02 -3.1E-01 9.8E-02 1.4E-03 
rs73091767 1 227250775 C T 0.2654 8.6E-06 9.4E-03 9.1E-02 5.2E-02 7.9E-02 
rs73099903 12 53440779 T C 0.0794 7.0E-05 7.6E-02 4.2E-01 8.8E-02 1.6E-06 
rs73161324 22 42038786 T C 0.0591 1.3E-05 1.5E-02 2.1E-01 1.2E-01 6.7E-02 
rs740406 19 2232221 G A 0.0631 9.6E-05 1.0E-01 5.5E-01 1.0E-01 6.9E-08 
rs7406910 17 46688256 C T 0.9107 1.0E-04 1.1E-01 4.9E-01 8.1E-02 1.9E-09 
rs740698 17 60767151 T C 0.5726 2.8E-05 3.0E-02 -1.5E-01 4.8E-02 2.2E-03 
rs745821 18 48142854 G T 0.2509 3.2E-05 3.5E-02 -1.8E-01 5.3E-02 7.5E-04 
rs7480089 11 45207851 A G 0.1222 3.1E-05 3.4E-02 -2.3E-01 7.2E-02 1.1E-03 
rs7500448 16 83045790 G A 0.2531 5.1E-05 5.6E-02 -2.3E-01 5.3E-02 2.4E-05 
rs7515635 1 42408070 C T 0.5316 7.6E-05 8.3E-02 -2.4E-01 4.6E-02 2.7E-07 
rs751984 11 61278246 C T 0.1211 1.1E-04 1.2E-01 -4.3E-01 7.4E-02 4.1E-09 
rs7562 2 28635740 C T 0.4703 3.2E-05 3.5E-02 -1.6E-01 4.7E-02 9.3E-04 
rs7592578 2 191439591 G T 0.7926 1.0E-04 1.1E-01 3.4E-01 6.0E-02 1.5E-08 
rs76206723 7 40447971 A G 0.1097 5.9E-05 6.4E-02 -3.4E-01 7.4E-02 6.4E-06 
rs76326501 2 43167878 C A 0.0891 1.3E-04 1.4E-01 -5.5E-01 8.3E-02 3.1E-11 
rs76452347 9 35906471 T C 0.2058 2.6E-05 2.8E-02 -1.7E-01 6.2E-02 5.8E-03 
rs76785029 12 94882905 T C 0.0717 2.2E-06 2.5E-03 -7.9E-02 9.7E-02 4.2E-01 
rs7777128 7 27337113 C G 0.0816 1.2E-04 1.3E-01 5.5E-01 8.4E-02 4.7E-11 
rs7810028 7 139461616 G C 0.1945 4.1E-05 4.5E-02 -2.2E-01 5.8E-02 1.5E-04 
rs78378222 17 7571752 G T 0.0164 2.9E-06 3.2E-03 -1.8E-01 2.1E-01 3.8E-01 
rs78648104 6 50683009 C T 0.1015 6.2E-05 6.8E-02 3.6E-01 8.3E-02 1.7E-05 
rs79089478 17 40317241 C T 0.0278 2.8E-06 3.1E-03 -1.4E-01 1.5E-01 3.4E-01 
rs7914287 10 69350563 C T 0.2303 2.1E-05 2.3E-02 1.5E-01 5.6E-02 7.8E-03 
rs79146658 2 179786068 C T 0.0821 8.2E-09 8.9E-06 4.5E-03 8.6E-02 9.6E-01 
rs7927515 11 76125330 A C 0.3455 3.5E-05 3.9E-02 1.7E-01 4.9E-02 4.8E-04 
rs7977389 12 49981722 C T 0.1065 1.4E-05 1.5E-02 -1.6E-01 7.5E-02 2.8E-02 
rs8059962 16 81574197 C T 0.5764 3.7E-05 4.1E-02 1.7E-01 4.7E-02 3.0E-04 
rs8105753 19 31927547 C A 0.3745 4.5E-05 4.9E-02 -1.9E-01 4.9E-02 9.9E-05 
rs8258 11 117283676 C T 0.6324 3.9E-06 4.3E-03 -5.6E-02 4.8E-02 2.4E-01 
rs869396 4 169688000 A C 0.4668 4.3E-05 4.7E-02 -1.8E-01 4.7E-02 1.1E-04 
rs871606 4 54799245 C T 0.1058 6.6E-05 7.2E-02 -3.6E-01 7.6E-02 2.2E-06 
rs880315 1 10796866 C T 0.348 3.3E-04 3.6E-01 5.2E-01 5.0E-02 1.3E-25 























rs891511 7 150704843 A G 0.3518 7.8E-05 8.5E-02 -2.5E-01 5.2E-02 1.2E-06 
rs894344 8 135612745 G A 0.4105 2.8E-05 3.0E-02 1.5E-01 4.7E-02 1.8E-03 
rs900145 11 13293905 T C 0.7041 1.4E-05 1.6E-02 1.1E-01 5.0E-02 2.3E-02 
rs917275 7 28658522 G A 0.3892 1.6E-05 1.8E-02 1.1E-01 4.8E-02 1.8E-02 
rs918466 3 64710253 A G 0.4105 2.5E-05 2.7E-02 -1.4E-01 4.8E-02 3.6E-03 
rs9306160 21 45107562 C T 0.6026 5.5E-05 6.0E-02 2.1E-01 4.7E-02 1.3E-05 
rs9323988 14 98587630 C T 0.3896 7.2E-05 7.9E-02 2.4E-01 4.6E-02 3.1E-07 
rs932764 10 95895940 G A 0.4439 1.8E-04 1.9E-01 3.7E-01 4.7E-02 4.8E-15 
rs9337951 10 30317073 A G 0.337 1.0E-05 1.1E-02 9.3E-02 5.3E-02 7.8E-02 
rs9349379 6 12903957 G A 0.4088 8.9E-05 9.8E-02 -2.6E-01 4.9E-02 6.4E-08 
rs9372498 6 118572486 A T 0.0848 5.4E-05 5.9E-02 3.6E-01 8.3E-02 1.4E-05 
rs9479200 6 152398505 G A 0.1231 5.6E-06 6.1E-03 9.9E-02 7.1E-02 1.7E-01 
rs9549328 13 113636156 T C 0.2345 4.6E-05 5.0E-02 2.2E-01 5.5E-02 8.6E-05 
rs956006 15 62808539 T C 0.336 5.8E-06 6.4E-03 -7.0E-02 4.9E-02 1.6E-01 
rs9662255 1 9441949 A C 0.4307 4.7E-05 5.1E-02 -1.9E-01 4.8E-02 9.4E-05 
rs9678851 2 27887034 A C 0.559 1.7E-05 1.9E-02 -1.1E-01 4.7E-02 1.7E-02 
rs9687065 5 148391140 G A 0.1957 5.3E-05 5.8E-02 -2.5E-01 5.9E-02 2.3E-05 
rs9729719 1 38298207 A G 0.2946 1.1E-05 1.3E-02 1.0E-01 5.3E-02 5.6E-02 
rs9810888 3 53635595 G T 0.5024 3.0E-05 3.3E-02 1.5E-01 4.6E-02 1.2E-03 
rs9815354 3 41912651 A G 0.1711 3.0E-06 3.3E-03 -6.3E-02 6.3E-02 3.2E-01 
rs9827472 3 56726646 T C 0.3577 3.3E-05 3.6E-02 -1.6E-01 4.9E-02 7.2E-04 
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Table S3. UK prevalence estimates used to calculate population impact of distributional shifts in 
blood pressure. 









280 45-64 2017 Health Survey for England 1 
Hemorrhagic Stroke (All) 84.7 50-69 2010 Global Burden of Disease 2 
Peripheral Vascular 




Aortic Valve Stenosis 96.0 45-64 2017 Health Survey for England 1 
Atrial Fibrillation 250 45-69 2017 Public Health England 4 




Dilated Cardiomyopathy 20.0 45-75 2014 British Heart Foundation 6 
Endocarditis 11 All agesa 2013 Hospital Episode Statistics 7 
Rheumatic Heart Disease 23.0 All agesa 2013 Hospital Episode Statistics 8 
Chronic Kidney Disease 700 45-64 2017 Health Survey for England 1 
a When no age group-specific estimates could be obtained, the total population prevalence was used. 
1. NHS Digital. Health Survey for England 2017. https://digital.nhs.uk/data-and-information/publications/statistical/health-
survey-for-england/2017.
2. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results.
http://ghdx.healthdata.org/gbd-results-tool. Published 2018. 
3. Cea-Soriano L, Fowkes FGR, Johansson S, Allum AM, García Rodriguez LA. Time trends in peripheral artery disease 
incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK.
BMJ Open. 2018;8(1):e018184. doi:10.1136/bmjopen-2017-018184 
4. Public Health England. Atrial fibrillation prevalence estimates in England : Application of recent population estimates of AF.
PHE Publ Gateway number 2014778. 2015;August:1-4. 
5. NHS Digital. Quality and Outcomes Framework, Achievement, prevalence and exceptions data - 2017-18.
https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-
prevalence-and-exceptions-data/2017-18.
6. Cardiomyopathy - British Heart Foundation. https://www.bhf.org.uk/informationsupport/conditions/cardiomyopathy.
7. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in
England, 2000-13: a secular trend, interrupted time-series analysis. Lancet. 2015;385(9974):1219-1228. doi:10.1016/S0140-
6736(14)62007-9 
8. Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology of cardiovascular disease in the
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Table S4. Mendelian randomization estimates (odds ratio with 95% confidence interval per 10 mmHg increase in genetically-predicted systolic 
blood pressure) using the inverse-variance weighted, MR-Egger, weighted median, and MR-PRESSO methods for 21 disease outcomes. 
Outcome 
Inverse-weighted 
variance MR-Egger Weighted median MR-PRESSO 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Coronary Artery Disease 1.59 (1.45-1.74) <0.001 1.44 (1.20-1.73) <0.001 1.61 (1.48-1.75) <0.001 1.59 (1.45-1.75) <0.001 
Ischemic Cerebrovascular 
Disease (all) 1.52 (1.39-1.66) <0.001 1.66 (1.40-1.98) <0.001 1.50 (1.33-1.70) <0.001 1.52 (1.39-1.66) <0.001 
Ischemic Stroke 1.70 (1.52-1.90) <0.001 1.86 (1.48-2.32) <0.001 1.78 (1.51-2.09) <0.001 1.71 (1.52-1.91) <0.001 
Transient Ischemic Attack 1.34 (1.19-1.51) <0.001 1.40 (1.10-1.79) 0.006 1.38 (1.15-1.64) <0.001 1.35 (1.19-1.52) <0.001 
Hemorrhagic Stroke (all) 1.43 (1.21-1.69) <0.001 1.39 (0.99-1.95) 0.05 1.33 (1.04-1.71) 0.02 1.42 (1.20-1.68) <0.001 
Intracerebral Hemorrhage 1.32 (1.06-1.66) 0.02 1.22 (0.78-1.91) 0.39 1.24 (0.88-1.74) 0.21 1.31 (1.04-1.64) 0.02 
Subarachnoid Hemorrhage 1.54 (1.22-1.94) <0.001 1.72 (1.09-2.72) 0.02 1.65 (1.17-2.32) 0.004 1.53 (1.22-1.94) <0.001 
Aortic Aneurysm (all) 1.26 (1.02-1.56) 0.03 1.51 (0.99-2.31) 0.06 1.39 (1.06-1.82) 0.02 1.28 (1.03-1.58) 0.02 
Abdominal Aortic Aneurysm 1.20 (0.93-1.56) 0.17 1.07 (0.64-1.79) 0.80 1.34 (0.95-1.88) 0.10 1.22 (0.94-1.58) 0.15 
Thoracic Aortic Aneurysm 1.19 (0.79-1.77) 0.41 1.99 (0.90-4.41) 0.09 1.34 (0.75-2.40) 0.33 1.23 (0.82-1.84) 0.31 
Venous Thromboembolism 
(all) 0.90 (0.80-1.01) 0.07 1.00 (0.79-1.25) 0.98 0.87 (0.78-0.96) 0.005 0.90 (0.80-1.01) 0.07 
Deep Vein Thrombosis 0.88 (0.77-1.00) 0.04 0.95 (0.74-1.22) 0.67 0.90 (0.80-1.02) 0.09 0.87 (0.77-0.99) 0.04 
Pulmonary Embolism 0.91 (0.79-1.05) 0.20 1.05 (0.79-1.38) 0.75 0.96 (0.83-1.11) 0.57 0.92 (0.80-1.05) 0.22 
Peripheral Vascular Disease 1.28 (1.11-1.46) <0.001 1.01 (0.77-1.32) 0.96 1.18 (0.98-1.43) 0.09 1.28 (1.11-1.47) <0.001 
Aortic Valve Stenosis 1.74 (1.48-2.04) <0.001 1.90 (1.38-2.62) <0.001 1.81 (1.43-2.29) <0.001 1.75 (1.49-2.05) <0.001 
Atrial Fibrillation 1.32 (1.21-1.42) <0.001 1.35 (1.15-1.58) <0.001 1.29 (1.17-1.42) <0.001 1.32 (1.21-1.43) <0.001 
Heart Failure 1.38 (1.25-1.53) <0.001 1.36 (1.12-1.67) 0.002 1.47 (1.28-1.69) <0.001 1.37 (1.24-1.51) <0.001 
Dilated Cardiomyopathy 1.61 (1.24-2.10) <0.001 2.57 (1.52-4.35) <0.001 1.60 (1.07-2.40) 0.02 1.58 (1.23-2.03) <0.001 
Endocarditis 1.49 (1.12-1.99) 0.007 1.41 (0.79-2.52) 0.24 1.47 (0.97-2.24) 0.07 1.52 (1.14-2.03) <0.001 
Rheumatic Heart Disease 1.32 (1.13-1.53) <0.001 1.55 (1.15-2.09) 0.004 1.43 (1.16-1.77) 0.001 1.31 (1.13-1.52) <0.001 
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Table S5. Population impact fractions (PIFs) for outcomes with strong evidence of causality for 
systolic blood pressure. The PIF represents the percentage reduction (with 95% confidence 
interval) in events if systolic blood pressure was 132.7 mmHg, 127.7 mmHg, and 115.0 mmHg for 
all individuals in the UK Biobank study sample, instead of the current mean systolic blood 
pressure of 137.7 mmHg. 
Outcomes
Percentage reduction in number of events attributable to 







Coronary Artery Disease 20.9 (17.3-24.4) 37.5 (31.6-42.9) 65.6 (57.8-72.0) 
Ischemic Cerebrovascular 
Disease (all)a 18.9 (15.2-22.5) 34.3 (28.1-40.0) 61.5 (52.7-68.6) 
Hemorrhagic Stroke (all)a 16.1 (8.6-22.9) 29.5 (16.5-40.5) 54.8 (33.5-69.3) 
Peripheral Vascular 
Disease 11.8 (5.4-17.7) 22.1 (10.4-32.3) 43.3 (22.1-58.7) 
Aortic Valve Stenosis 24.4 (18.1-30.2) 42.9 (33.0-51.3) 72.0 (59.7-80.5) 
Atrial Fibrillation 12.6 (9.1-16.5) 23.7 (17.3-30.2) 45.8 (35.0-55.8) 
Heart Failure 14.4 (10.0-18.5) 26.7 (18.9-33.6) 50.5 (37.9-60.6) 
Dilated Cardiomyopathy 20.5 (9.1-30.2) 36.9 (17.3-51.3) 64.8 (35.0-80.5) 
Endocarditis 18.9 (6.3-29.9) 34.2 (12.2-50.8) 61.4 (25.6-80.0) 
Rheumatic Heart Disease 12.6 (5.8-18.9) 23.7 (11.3-34.3) 45.8 (23.9-61.5) 
Chronic Kidney Disease 15.2 (10.4-19.8) 28.1 (19.8-35.7) 52.7 (39.3-63.2) 
Total 16.9 (12.2-21.3) 30.8 (22.8-38.0) 56.2 (43.7-65.9) 
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Figure S1. Summary of the data sources for this study and the assumptions of the Mendelian 
randomization design. Broken lines represent potential pleiotropic or direct causal effects between 
variables that would violate the Mendelian randomization assumptions. 
*The number of cases for each outcome is reported in parentheses. 
 GWAS, Genome-wide association study; ICBP, International Blood Pressure 
Consortium; ICD, International Classification of Disease; OPCS, Office of Population Censuses and 
Surveys Classification of Surgical Operations and Procedures; SBP, systolic blood pressure; SNP, 
single nucleotide polymorphism; UKBB, UK Biobank.  
Assumption 1 
Genetic variants are 
robustly associated 
with the modified risk 
factor
Genetic instrument 
256 SNPs associated with systolic blood 
pressure at genome-wide statistical significance 
in 299,024 participants of European ancestry 
(ICBP GWAS)
Modifiable risk factor 
Systolic blood pressure
Disease outcomes*
Recorded in 367,703 participants in UKBB via 
self-report, ICD-9 death/diagnosis, ICD-10 
death/diagnosis, or OPCS procedure 
Coronary Artery Disease (29,278)
Ischemic Cerebrovascular Disease (all) (8,084) 
Ischemic Stroke (4,602) 
Transient Ischemic Attack (3,962) 
Hemorrhagic Stroke (all) (1,981) 
Intracerebral Hemorrhage (1,064) 
Subarachnoid Hemorrhage (1,084)
Aortic Aneurysm (all) (1,849) 
Abdominal Aortic Aneurysm (1,094) 
Thoracic Aortic Aneurysm (347)
Venous Thromboembolism (all) (14,097) 
Deep Vein Thrombosis (9,454) 
Pulmonary Embolism (6,148) 
Peripheral Vascular Disease (3,415)
Aortic Valve Stenosis (2,244) 
Atrial Fibrillation (16,945) 
Heart Failure (6,712) 
Dilated Cardiomyopathy (720)
Endocarditis (691)
Rheumatic Heart Disease (2,817)







affect the outcome 
only through SBP 




Genetic variants are 
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Figure S2. Distribution of systolic blood pressure in UK Biobank. Overall mean systolic blood 
pressure is 137.7 mmHg (standard deviation 18.6 mmHg); female mean systolic blood pressure is 
135.0 mmHg (standard deviation 19.2); male mean systolic blood pressure is 140.8 (standard 
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(a)    (b) 
(c)     (d) 
(e)     (f) 
(g)     (h) 
Figure S3 (a)-(m). Scatter plots of the beta-coefficients for the exposure plotted against the beta-coefficients for the 
outcome for each of the 256 SNPs in the instrument. Each dot corresponds to a SNP. Lines represent the 95% CI for 
each SNP’s beta-coefficient. Each scatter plot corresponds to one outcome: (a) Coronary artery disease; (b) Ischemic 
cerebrovascular disease (all); (c) Ischemic stroke; (d) Transient ischemic attack; (e) Hemorrhagic stroke (all); (f) Intracerebral 
hemorrhage; (g) Subarachnoid hemorrhage; (h) Aortic aneurysm (all); (i) Abdominal aortic aneurysm; (j) Thoracic aortic 
aneurysm; (k) Venous thromboembolism (all); (l) Deep vein thrombosis; (m) Pulmonary embolism; (n) Peripheral vascular 
disease; (o) Aortic valve stenosis; (p) Atrial fibrillation; (q) Heart failure; (r) Dilated cardiomyopathy; (s) Endocarditis; (t) 
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(i)     (j) 
(k)    (l) 
(m)     (n) 
(o)     (p) 
Figure S3 (contd.) (a)-(m). Scatter plots of the beta-coefficients for the exposure plotted against the beta-coefficients 
for the outcome for each of the 256 SNPs in the instrument. Each dot corresponds to a SNP. Lines represent the 95% CI 
for each SNP’s beta-coefficient. Each scatter plot corresponds to one outcome: (a) Coronary artery disease; (b) Ischemic 
cerebrovascular disease (all); (c) Ischemic stroke; (d) Transient ischemic attack; (e) Hemorrhagic stroke (all); (f) Intracerebral 
hemorrhage; (g) Subarachnoid hemorrhage; (h) Aortic aneurysm (all); (i) Abdominal aortic aneurysm; (j) Thoracic aortic 
aneurysm; (k) Venous thromboembolism (all); (l) Deep vein thrombosis; (m) Pulmonary embolism; (n) Peripheral vascular 
disease; (o) Aortic valve stenosis; (p) Atrial fibrillation; (q) Heart failure; (r) Dilated cardiomyopathy; (s) Endocarditis; (t) 
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(q)     (r) 
(s)     (t) 
(u) 
Figure S3 (contd.) (a)-(m). Scatter plots of the beta-coefficients for the exposure plotted against the beta-coefficients 
for the outcome for each of the 256 SNPs in the instrument. Each dot corresponds to a SNP. Lines represent the 95% CI 
for each SNP’s beta-coefficient. Each scatter plot corresponds to one outcome: (a) Coronary artery disease; (b) Ischemic 
cerebrovascular disease (all); (c) Ischemic stroke; (d) Transient ischemic attack; (e) Hemorrhagic stroke (all); (f) Intracerebral 
hemorrhage; (g) Subarachnoid hemorrhage; (h) Aortic aneurysm (all); (i) Abdominal aortic aneurysm; (j) Thoracic aortic 
aneurysm; (k) Venous thromboembolism (all); (l) Deep vein thrombosis; (m) Pulmonary embolism; (n) Peripheral vascular 
disease; (o) Aortic valve stenosis; (p) Atrial fibrillation; (q) Heart failure; (r) Dilated cardiomyopathy; (s) Endocarditis; (t) 
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